Please login to the form below
Takeda files US patent case
Takeda sues Dr Reddy's over patent infringements related to Dexilant drug
Takeda Pharmaceutical has filed a patent infringement suit against India's Dr Reddy's Laboratories in a New York court. The suit relates to efforts from Dr Reddy's to manufacture a generic version of Takeda's acid reflux treatment drug Dexilant (dexlansoprazole).
Takeda alleges that the Indian generic-drug maker and its US subsidiary have infringed US patent numbers through the submission of an abbreviated new drug application seeking approval to market generic versions of Dexilent.
The drug has an annual market size of more than $300m in the US market, according to IMS Health figures.
Dr Reddy's was unavailable for comment at the time of writing.
Share
Related Hub content
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
